Therapies and Biomarkers for Inflammatory Bowel Disease

December 27, 2012

Wellesley, Mass. – According to a new technical market research report, THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE (PHM125A), from BCC Research (www.bccresearch.com), the market for inflammatory bowel disease therapeutics was valued at $4.8 billion in 2011 and should reach nearly $5.1 billion in 2012. Total market value is expected to reach nearly $6.2 billion in 2017 after increasing at a five-year compound annual growth rate of 4.1%.

The market for inflammatory bowel disease therapeutics can be broken down into four main segments: United States, Japan, EU5, and the rest of the world.

The therapeutics market for inflammatory bowel disease in the United States should reach $2.5 billion in 2012 and nearly $3.2 billion in 2017, a CAGR of 4.8%.

The Japan segment is expected to reach $538 million in 2012 and $625 million in 2017, a CAGR of 3%.

As a segment, the EU5 (France, Germany, Italy, Spain, and the United Kingdom) is expected to total $1.1 billion in 2012 and nearly $1.4 billion in 2017, a CAGR of 3.8%.

IBD is made up of of two major disorders: Crohn’s disease and ulcerative colitis, in which the intestinal tract experiences severe and chronic inflammation. Both diseases have distinct pathologic and clinical characteristics, and despite decades of research into their origins, disease pathogenesis for both conditions remains poorly understood.

There is currently no cure for IBD; thus,  the primary goal of disease management is to minimize complications and unnecessary suffering. As a disease class, IBD is distinct from irritable bowel syndrome (IBS), although the two share some symptoms. IBD causes irreversible damage to the bowel and healthcare utilization. Disease-associated morbidity is significant for those with this progressive and difficult-to-manage disease.

This report will help its readers:

• Understand in-depth analysis of the intellectual property landscape for major industry players. This report highlights recent industrial shifts (e.g., strategic alliances, mergers and acquisitions, major venture capital deals) in the IBD diagnostic and therapeutic space.
• Determine the scope of the market from profiles of numerous smaller specialized market players in this report. Market segmentation within the areas of therapeutic class and geographical areas are highlighted. 

This report will be valuable to many industry participants, including the following:

• IBD therapeutics producers and consumers
• IBD diagnostics manufacturers
• Academic and research institutions
• End users and distributors
• Financial institutions.

To Contact us, click here  

Therapies and Biomarkers for Inflammatory Bowel Disease( PHM125A )
Publish Date: Jan 2013    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.